Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Action Potential Venture Capital (APVC) was founded in 2013 as the corporate venture arm of GlaxoSmithKline (GSK), focusing on bioelectronic medicines and enabling technologies. The firm is based in the United States and has a strong commitment to investing in innovative healthcare solutions. In 2016, APVC transitioned to an independent structure known as Synapse Fund, continuing its focus on advancing bioelectronic medicine.
Initially launched with $50 million from GSK, APVC has made significant strides in the healthcare sector, particularly in bioelectronics. The firm has a history of investing in early-stage companies that develop technologies aimed at improving health outcomes. Notable milestones include the successful investments in companies like SetPoint Medical, CVRx, and Cala Health, which have contributed to the firm's reputation in the healthcare investment space.
As of now, APVC operates with a focus on early-stage investments, primarily targeting pre-seed, seed, and seed-plus stages. The firm is backed by notable partners and has a strong foundation in healthcare technology, making it a key player in the bioelectronic medicine sector.
Action Potential Venture Capital specializes in early-stage investments within the healthcare sector, particularly in bioelectronic medicines and enabling technologies. The firm targets companies at the pre-seed, seed, and seed-plus stages, focusing on innovative solutions that improve health outcomes. Their investment strategy emphasizes the intersection of healthcare and technology, with a keen interest in areas such as digital health, therapeutics, and medical devices.
APVC's investment thesis is centered on bioelectronic medicines, which include implanted neuromodulation devices and wearable bioelectronic systems. The firm seeks to invest in startups that are developing technologies capable of modulating electrical signals in the nervous system to treat various diseases. This focus on bioelectronics positions APVC uniquely within the healthcare investment landscape, as they bridge the gap between pharmaceuticals, medical devices, and neuroscience.
Action Potential Venture Capital has invested in several notable companies within the healthcare sector, focusing on bioelectronic medicines. The firm's portfolio includes:
These companies exemplify APVC's commitment to advancing healthcare through innovative technologies. Each portfolio company addresses significant health challenges, showcasing the firm's strategic focus on improving health outcomes through bioelectronic solutions.
David M. Stout - Managing Partner. David has extensive experience in venture capital and healthcare, having previously worked with GSK. He specializes in bioelectronic medicines and has led several successful investments in the sector.
Jennifer A. Dyer - Partner. Jennifer brings a wealth of knowledge in healthcare technology and investment strategy. Her background includes roles in both corporate and venture capital settings, focusing on early-stage healthcare startups.
Michael J. McGinnis - Partner. Michael has a strong track record in healthcare investments, particularly in bioelectronics. His expertise lies in identifying innovative technologies that can transform patient care.
To pitch Action Potential Venture Capital, founders should visit their website at actionpotentialvc.com. It is recommended to include a detailed pitch deck that outlines the technology, market opportunity, competitive landscape, and team qualifications. While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's focus on early-stage investments.
As of 2023, Action Potential Venture Capital has transitioned to an independent structure known as Synapse Fund, continuing its focus on bioelectronic medicines. This change reflects the firm's commitment to advancing healthcare technology while maintaining its core investment thesis.
Recent investments include notable companies in the bioelectronic space, such as SetPoint Medical and CVRx, which have made significant advancements in their respective fields. The firm remains active in seeking new opportunities within the healthcare sector.
What are Action Potential Venture Capital's investment criteria?
APVC invests in early-stage companies developing bioelectronic medicines and enabling technologies. They focus on startups at the pre-seed, seed, and seed-plus stages, particularly those innovating in healthcare technology.
How can founders apply or pitch to Action Potential Venture Capital?
Founders can pitch their ideas through the firm's website at actionpotentialvc.com. It is advisable to include a comprehensive overview of the technology, market potential, and team background in the pitch deck.
What makes Action Potential Venture Capital different from other investors?
APVC's unique focus on bioelectronic medicines sets it apart from other venture capital firms. Their expertise in healthcare technology and backing by GSK provide additional credibility and potential for co-investment opportunities.
What is the geographic scope of Action Potential Venture Capital's investments?
The firm primarily invests in companies based in the United States, focusing on innovative healthcare solutions that improve health outcomes.
What is the typical check size for investments made by Action Potential Venture Capital?
While specific check sizes are not disclosed, APVC typically invests in early-stage rounds, which can range from hundreds of thousands to several million dollars, depending on the stage and potential of the startup.
What type of post-investment involvement does Action Potential Venture Capital have?
APVC provides strategic support and resources to its portfolio companies, leveraging its expertise in bioelectronics and healthcare technology to foster innovation and growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.